Cleo Diagnostics Boosts Biomarker Panel from 5 to 8 Markers for FDA Push
Cleo Diagnostics has expanded its ovarian cancer biomarker panel from five to eight markers, enhancing test reliability and gearing up for FDA submission. A manufacturing deal is imminent, setting the stage for commercial rollout.
- Biomarker panel expanded to eight markers for improved robustness
- Optimised for high-throughput Ella™ platform to enable scalability
- Manufacturing agreement with experienced partner expected imminently
- Test kit production to begin supporting FDA analytical validation
- Advances towards planned FDA 510(k) submission and U.S. market entry
Expanding the Diagnostic Arsenal
Cleo Diagnostics Limited (ASX:COV) has taken a significant step forward in its mission to revolutionise ovarian cancer diagnosis. The company announced the expansion and optimisation of its biomarker panel underpinning its Pre-Surgical Ovarian Cancer Test, increasing the number of biomarkers from five to eight. This enhancement is designed to improve the test’s analytical robustness and reproducibility, critical factors for regulatory approval and clinical adoption.
The original panel, anchored by Cleo’s patented CXCL10 biomarker, already demonstrated strong diagnostic capabilities in distinguishing benign from malignant ovarian conditions. By broadening the panel, Cleo aims to reduce reliance on any single biomarker, thereby mitigating variability and technical risks often encountered in early assay development.
Leveraging Advanced Technology for Scale
The expanded panel is tailored for the Ella™ immunoassay platform, a next-generation microfluidic system that allows simultaneous measurement of multiple biomarkers from a single sample. This technology supports high throughput without compromising workflow efficiency or sample utilisation, positioning Cleo for scalable global deployment.
Importantly, the company has aligned closely with a preferred manufacturing partner experienced in producing assays for the selected biomarkers. This collaboration is expected to reduce scale-up risks and accelerate the transition from research to commercial-ready test kits.
On the Cusp of Regulatory Milestones
A binding manufacturing agreement is anticipated imminently, which will enable the production of test kits to support FDA analytical validation activities. This is a crucial precursor to Cleo’s planned FDA 510(k) submission, a regulatory pathway that could open the lucrative U.S. market for the company’s diagnostic test.
CEO Dr Richard Allman emphasised the milestone’s significance, highlighting the improved assay robustness and reproducibility under real-world conditions. He also noted that the Ella™ platform’s capabilities have allowed the company to enhance its biomarker panel without sacrificing operational efficiency.
With ovarian cancer remaining a challenging disease to detect early, Cleo’s advancements could have meaningful clinical implications. An accurate, simple blood test that distinguishes benign from malignant ovarian growths could transform patient outcomes by enabling earlier and more precise surgical decisions.
As Cleo moves closer to regulatory submission and commercialisation, the market will be watching how effectively the company navigates manufacturing scale-up and validation hurdles.
Bottom Line?
Cleo’s biomarker expansion and manufacturing alignment mark a pivotal step toward FDA approval and market entry, but execution risks remain.
Questions in the middle?
- When exactly will the manufacturing agreement be signed and production commence?
- How will the expanded biomarker panel perform in large-scale clinical validation?
- What is the anticipated timeline for FDA 510(k) submission and approval?
